Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Quince Therapeutics (QNCX)
NASDAQ:QNCX
Holding QNCX?
Track your performance easily
QNCX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.51 - $2.45
Previous Close$1.96
Volume528.00K
Average Volume (3M)524.11K
Market Cap
$86.24M
Enterprise Value$56.42M
Total Cash (Recent Filing)$45.17M
Total Debt (Recent Filing)$15.35M
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Mar 04, 2025EPS Estimate
-$0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.25
Shares Outstanding44,001,643
10 Day Avg. Volume361,731
30 Day Avg. Volume524,113
Standard Deviation0.33
R-Squared0.01
Alpha0.00537
Financial Highlights & Ratios
Price to Book (P/B)1.80
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.22
Forecast
1Y Price Target
$9.67Price Target Upside388.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Quince Therapeutics News
Bulls Say, Bears Say
Bulls Say
Potential UpsideThe EryDex P3 NEAT study is seen as partially de-risked, with potential upside in QNCX shares on the A-T program alone.
Regulatory MilestoneFDA granted SPA for the P3 NEAT trial, which is a significant regulatory milestone for the program.
Safety And TolerabilityThe AIDE technology allows for a simple and safe point-of-care system, with over 50 patients on EryDex showing no safety issues.
Bears Say
Adverse EventsPatients in the study experienced treatment-emergent adverse events, including pyrexia, tachycardia, pain, and pruritus, raising concerns about the treatment's safety profile.
Clinical TrialsThe EryDex P3 study is based on previous difficulties with the ATTeST P3 trial, which did not meet its primary goals.
Study DiscontinuationsThree patients were removed from the study due to adverse events, including serious conditions such as B-cell lymphoma and probable treatment-related issues like tachycardia.
---
Ownership Overview
18.09% Insiders
3.56% Mutual Funds
4.24% Other Institutional Investors
71.20% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
QNCX FAQ
What was Quince Therapeutics’s price range in the past 12 months?
Quince Therapeutics lowest stock price was $0.51 and its highest was $2.45 in the past 12 months.
What is Quince Therapeutics’s market cap?
Currently, no data Available
When is Quince Therapeutics’s upcoming earnings report date?
Quince Therapeutics’s upcoming earnings report date is Mar 04, 2025 which is in 97 days.
How were Quince Therapeutics’s earnings last quarter?
Quince Therapeutics released its earnings results on Nov 13, 2024. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.173 by $0.043.
Is Quince Therapeutics overvalued?
According to Wall Street analysts Quince Therapeutics’s price is currently Undervalued.
Does Quince Therapeutics pay dividends?
Quince Therapeutics does not currently pay dividends.
What is Quince Therapeutics’s EPS estimate?
Quince Therapeutics’s EPS estimate is -$0.18.
How many shares outstanding does Quince Therapeutics have?
Quince Therapeutics has 44,001,644 shares outstanding.
What happened to Quince Therapeutics’s price movement after its last earnings report?
Quince Therapeutics reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.173. Following the earnings report the stock price went up 19.497%.
Which hedge fund is a major shareholder of Quince Therapeutics?
Currently, no hedge funds are holding shares in QNCX
---
Quince Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.67 (388.38% Upside)
$9.67 (388.38% Upside)
Blogger Sentiment
Bullish
QNCX Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth $107.4K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
117.77%
12-Months-Change
Fundamentals
Return on Equity
-83.18%
Trailing 12-Months
Asset Growth
48.17%
Trailing 12-Months
Company Description
Quince Therapeutics
Cortexyme, Inc. is a biopharmaceutical company, which develops therapeutics based on data supporting a new theory of the cause of Alzheimer's and other neurodegenerative disorders. Its product, COR388, is in clinical trial. The company was founded by Casey Crawford Lynch, Stephen Dominy, and Kristen Gafric on June 20, 2012 and is headquartered in South San Francisco, CA.
---
QNCX Stock 12 Month Forecast
Average Price Target
$9.67
▲(388.38% Upside)
Technical Analysis
Best Analysts Covering QNCX
1 Year
1 Year Success Rate
1/1 ratings generated profit
1 Year Average Return
+130.50%
initiated a buy rating last month
Copying Jason Kolbert's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +130.50% per trade.
---